CSL enters global lixudebart partnership with Alentis, pays US$355 million upfront
Bitget2026/10/04 21:42CSL entered an exclusive global collaboration with Alentis Therapeutics to co-develop, co-promote lixudebart for rare kidney and liver diseases. Deal includes an upfront payment of US$355 million, up to US$1.2 billion in commercial milestones, with global profits split 55% CSL, 45% Alentis. CSL will fund the Phase 2 RENAL trial completion, a planned Phase 3 in AAV-RPGN, with additional Phase 2 studies in FSGS, PSC. Lixudebart targets claudin-1, positioned as a potential first-in-class therapy with anti-inflammatory, anti-fibrotic effects across organ fibrosis indications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSL Limited published the original content used to generate this news brief via CNW (Ref. ID: 202610041742CANADANWCANADAPR_C2919) on October 04, 2026, and is solely responsible for the information contained therein.
- CSL entered an exclusive global collaboration with Alentis Therapeutics to co-develop, co-promote lixudebart for rare kidney and liver diseases.
- Deal includes an upfront payment of US$355 million, up to US$1.2 billion in commercial milestones, with global profits split 55% CSL, 45% Alentis.
- CSL will fund the Phase 2 RENAL trial completion, a planned Phase 3 in AAV-RPGN, with additional Phase 2 studies in FSGS, PSC.
- Lixudebart targets claudin-1, positioned as a potential first-in-class therapy with anti-inflammatory, anti-fibrotic effects across organ fibrosis indications.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
British Pound hits session highs at 1.3420 amid broadbased US Dollar weakness
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Crypto prices
More
